Terms: = Lung cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Clinical Outcome
31 results:
1. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
2. Immune Features of Tumor Microenvironment: A Genetic Spotlight.
Asadi M; Zarredar H; Zafari V; Soleimani Z; Saeedi H; Caner A; Shanehbandi D
Cell Biochem Biophys; 2024 Mar; 82(1):107-118. PubMed ID: 37870699
[TBL] [Abstract] [Full Text] [Related]
3. Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC.
Devi-Marulkar P; Fastenackels S; Karapentiantz P; Goc J; Germain C; Kaplon H; Knockaert S; Olive D; Panouillot M; Validire P; Damotte D; Alifano M; Murris J; Katsahian S; Lawand M; Dieu-Nosjean MC
Commun Biol; 2022 Dec; 5(1):1416. PubMed ID: 36566320
[TBL] [Abstract] [Full Text] [Related]
4. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract] [Full Text] [Related]
5. Identification and functional analysis of lncRNAs and mRNAs between tumorigenesis and metastasis in CRC.
Liu H; Tian Y; Li J; Zhang G; Liu Q; Yang M; Yue L; Cao Q; Zhang G; Cheng Y; Kong N; Fang L; Li S; Sun Q
Aging (Albany NY); 2021 Dec; 13(24):25859-25885. PubMed ID: 34954693
[TBL] [Abstract] [Full Text] [Related]
6. Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases.
Stift J; Graf A; Neudert B; Herac M; Woeran K; Tamandl D; Laengle J; Schwarz C; Wrba F; Kaczirek K; Stremitzer S
HPB (Oxford); 2022 Jan; 24(1):40-46. PubMed ID: 34158230
[TBL] [Abstract] [Full Text] [Related]
7. PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Minari R; Bonatti F; Mazzaschi G; Dodi A; Facchinetti F; Gelsomino F; Cinquegrani G; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Quaini F; Ardizzoni A; Tiseo M
Tumori; 2022 Feb; 108(1):47-55. PubMed ID: 34002648
[TBL] [Abstract] [Full Text] [Related]
8. [The impact of CD8 and ctla-4 expression on histopathological character and survival in mesothelioma].
Yu M; Yu M; Ying SB; Yuan XY; Jiang ZQ; Lou JL; Zhu LJ; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):85-90. PubMed ID: 33691360
[No Abstract] [Full Text] [Related]
9. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Hurkmans DP; Verdegaal EME; Hogan SA; de Wijn R; Hovestad L; van den Heuvel DMA; Ruijtenbeek R; Welters MJP; van Brakel M; Basak EA; Pinedo HM; Lamers CHJ; van de Werken HJG; Groten JP; Debets R; Levesque MP; Dummer R; Kapiteijn E; Mathijssen RHJ; Aerts JGJV; van der Burg SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427690
[TBL] [Abstract] [Full Text] [Related]
10. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
[TBL] [Abstract] [Full Text] [Related]
12. The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic cancers.
Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748
[TBL] [Abstract] [Full Text] [Related]
13. Novel immune subtypes of lung adenocarcinoma identified through bioinformatic analysis.
Qin FL; Xu ZY; Yuan LQ; Chen WJ; Wei JB; Sun Y; Li SK
FEBS Open Bio; 2020 Sep; 10(9):1921-1933. PubMed ID: 32686362
[TBL] [Abstract] [Full Text] [Related]
14. [Construction, expression and purification of a mammalian secretory recombinant fusion protein rPC].
Li C; Xie Y; Cao J; Shao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):969-978. PubMed ID: 32567280
[TBL] [Abstract] [Full Text] [Related]
15. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract] [Full Text] [Related]
16. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell lung cancer.
Ottonello S; Genova C; Cossu I; Fontana V; Rijavec E; Rossi G; Biello F; Dal Bello MG; Tagliamento M; Alama A; Coco S; Boccardo S; Vanni I; Ferlazzo G; Moretta L; Grossi F; Mingari MC; Carrega P; Pietra G
Front Immunol; 2020; 11():125. PubMed ID: 32117275
[TBL] [Abstract] [Full Text] [Related]
17. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell lung cancer Patients.
de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
[TBL] [Abstract] [Full Text] [Related]
18. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer.
Machado-Rugolo J; Fabro AT; Ascheri D; Farhat C; Ab'Saber AM; de Sá VK; Nagai MA; Takagaki T; Terra R; Parra ER; Capelozzi VL
Hum Pathol; 2019 Jan; 83():177-191. PubMed ID: 30218756
[TBL] [Abstract] [Full Text] [Related]
19. Resident memory T cells, critical components in tumor immunology.
Mami-Chouaib F; Blanc C; Corgnac S; Hans S; Malenica I; Granier C; Tihy I; Tartour E
J Immunother Cancer; 2018 Sep; 6(1):87. PubMed ID: 30180905
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer.
Rutkowski J; Cyman M; Ślebioda T; Bemben K; Rutkowska A; Gruchała M; Kmieć Z; Pliszka A; Zaucha R
Cell Immunol; 2017 Dec; 322():26-33. PubMed ID: 28939130
[TBL] [Abstract] [Full Text] [Related]
[Next]